Pacific Biosciences of California Inc (PACB)

[paulieme60]

2017 Jan 3. doi: 10.1002/humu.23166. [Epub ahead of print]
Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Abstract
CYP2D6 is among the most important genes involved in drug metabolism. Specific variants are associated with changes in the enzyme's amount and activity. Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR or Second-Generation Sequencing. However, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays. To circumvent this, we sequenced CYP2D6 using the Pacific Biosciences RSII and obtained high-quality, full-length, phased CYP2D6 sequences, enabling accurate variant calling and haplotyping of the entire gene-locus including exonic, intronic and up and downstream regions. Unphased diplotypes (Roche AmpliChip CYP450 test) were confirmed for 24 of 25 samples, including gene duplications. Cases with gene deletions required additional specific assays to resolve. In total, 61 unique variants were detected, including variants that had not previously been associated with specific haplotypes. To further aid genomic analysis using standard reference sequences we have established an LOVD-powered CYP2D6 gene-variant database and added all reference haplotypes and data reported here. We conclude that our CYP2D6 genotyping approach produces reliable CYP2D6 diplotypes and reveals information about additional variants, including phasing and copy-number variation. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
CYP2D6; PacBio long read sequencing; Pharmacogenomics; copy number variation; variant phasing https://www.ncbi.nlm.nih.gov/pubmed/28044414?dopt=Abstract